Inhibitors of glutaminase or transaminase have shown the therapeutic efficacy in multiple MYC-driven tumor models, and a representative glutaminase inhibitor, CB-839, is currently under clinical trials for patient treatment.106. This evidence concerns the gene MYC and neoplasm.